Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction

被引：13

作者：

Bedrouni, Wassim ^{[1
]}

Sharma, Abhinav ^{[2
]}

Pitt, Bertram ^{[3
]}

Lam, Carolyn S. P. ^{[4
,5
]}

Ni, Jiayi ^{[2
]}

Ferreira, Joao Pedro ^{[6
,7
,8
]}

McMurray, John ^{[9
]}

Giannetti, Nadia ^{[6
,7
]}

Girerd, Nicolas ^{[2
]}

Rossignol, Patrick ^{[6
,7
]}

Solomon, Scott D. ^{[10
]}

Claggett, Brian ^{[10
]}

Pocock, Stuart ^{[11
]}

Huynh, Thao ^{[2
]}

Zannad, Faiez ^{[6
,7
]}

机构：

[1] McGill Univ, Hlth Ctr, Dept Med, Montreal, PQ, Canada

[2] McGill Univ, Hlth Ctr, Div Cardiol, Montreal, PQ, Canada

[3] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI USA

[4] Natl Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore

[5] Duke Natl Univ Singapore, Singapore, Singapore

[6] Univ Lorraine, Invest Clin Plurithemat 1433, Nancy, France

[7] Univ Lorraine, Inserm U1116, CHRU Nancy, FCRIN INI CRCT Cardiovasc & Renal Clin Trialists, Nancy, France

[8] Univ Porto, Fac Med, Dept Surg & Physiol, Cardiovasc Res & Dev Ctr, Porto, Portugal

[9] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow, Scotland

[10] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA

[11] London Sch Hyg & Trop Med, Dept Med Stat, London, England

来源：

CIRCULATION-HEART FAILURE | 2022年 / 15卷 / 10期

关键词：

eplerenone; morbidity; myocardial infarction; prognosis; spironolactone; SPIRONOLACTONE; DYSFUNCTION; EPLERENONE; MORTALITY;

D O I：

10.1161/CIRCHEARTFAILURE.121.009295

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 5 条

[1] Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [J].

Pitt, B ;

Remme, W ;

Zannad, F ;

Neaton, J ;

Martinez, F ;

Roniker, B ;

Bittman, R ;

Hurley, S ;

Kleiman, J ;

Gatlin, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1309-1321

[2] Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure [J].

Pitt, B ;

White, H ;

Nicolau, J ;

Martinez, F ;

Gheorghiade, M ;

Aschermann, M ;

van Veldhuisen, DJ ;

Zannad, F ;

Krum, H ;

Mukherjee, R ;

Vincent, J .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (03) :425-431

[3] The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].

Pitt, B ;

Zannad, F ;

Remme, WJ ;

Cody, R ;

Castaigne, A ;

Perez, A ;

Palensky, J ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717

[4] Spironolactone for Heart Failure with Preserved Ejection Fraction [J].

Pitt, Bertram ;

Pfeffer, Marc A. ;

Assmann, Susan F. ;

Boineau, Robin ;

Anand, Inder S. ;

Claggett, Brian ;

Clausell, Nadine ;

Desai, Akshay S. ;

Diaz, Rafael ;

Fleg, Jerome L. ;

Gordeev, Ivan ;

Harty, Brian ;

Heitner, John F. ;

Kenwood, Christopher T. ;

Lewis, Eldrin F. ;

O'Meara, Eileen ;

Probstfield, Jeffrey L. ;

Shaburishvili, Tamaz ;

Shah, Sanjiv J. ;

Solomon, Scott D. ;

Sweitzer, Nancy K. ;

Yang, Song ;

McKinlay, Sonja M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (15) :1383-1392

[5] Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. [J].

Zannad, Faiez ;

McMurray, John J. V. ;

Krum, Henry ;

van Veldhuisen, Dirk J. ;

Swedberg, Karl ;

Shi, Harry ;

Vincent, John ;

Pocock, Stuart J. ;

Pitt, Bertram .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (01) :11-21

← 1 →